Search results
Sen. Welch aims to combat ‘patent thicketing’ to lower prescription drug prices
WCAX-TV Vermont· 4 hours agoVermont Senator Peter Welch and Senate Judiciary Committee colleagues held a hearing Tuesday on the...
It's Time for Over-the-Counter Ozempic
Reason.com via AOL· 3 hours agoBut when insurers foot the bills, consumers are less willing to switch to cheaper medications and competition fails. Knowing this, drug makers can demand...
Senators blame sky-high drug prices on abuse of the patent system
NBC News via Yahoo News· 16 hours agoThe drug industry’s top lobbying group faced fierce questioning at a Senate Judiciary Committee...
How Drug Companies Stifle Competition With ‘Product Hopping’
Forbes· 1 day agoActavis had spent that sum to acquire Forest and its portfolio of pharmaceutical products. Forest...
Bipartisan Focus on Drug Prices Continues with Proposed Expansion of Federal Authority Over Patent...
JD Supra· 2 days agoAs we previously covered in a LawFlash, the Bayh-Dole Act applies when businesses and other organizations (inventors) conduct research and...
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade
InvestorPlace· 6 days agoFor example, inventors of technology developed with federal funding retain rights to the patents....
Hims & Hers is selling an Ozempic knockoff without FDA approval. Here's how
Quartz· 21 hours agoThe millennial-skewed telehealth platform Hims & Hers this week joined several online pharmacies in...
Cost and Loqtorzi: How to find savings, lower costs, and more
Healthline· 5 days agoLoqtorzi (toripalimab-tpzi) is a prescription drug that treats cancer of your nasopharynx (upper throat behind your nose). Loqtorzi’s cost may depend on ...
Hims Debuts $199 Weight-Loss Shots at 85% Discount to Wegovy
The Business of Fashion· 1 day agoIn just a few years, Hims & Hers Health Inc. reached almost $1 billion in sales by making it easy to...
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks...
Benzinga· 4 days agoPresident Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule...
